Compare AstraZeneca plc (AZN) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Exxon Mobil Corporation — how do they compare? AstraZeneca plc trades at $157.69 (market cap $245.16B), while Exxon Mobil Corporation trades at $158.75 (market cap $656.88B). The key difference: Exxon Mobil Corporation is far larger — about 2.7× AstraZeneca plc's market cap, and Exxon Mobil Corporation pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| AZN | XOM | |
|---|---|---|
Market Cap | $245.16B | $656.88B |
Sector | Health | Energy |
52-Week High | $209.48 | $171.52 |
52-Week Low | $147.06 | $106.49 |
Enterprise Value | $272.43B | $688.66B |
Dividend Yield | 2.02% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
ExxonMobil (XOM) trades at $159.8, up 0.01% on the day, with a bullish technical signal and strong cash flow from operations of $52.0 billion in 2025. Recent earnings show mixed results, with a Q2 2026 miss but beats in prior quarters. The company maintains a solid balance sheet with a debt-to-asset ratio of 8.42% and continues shareholder returns via dividends, including the recent $1.03 per share payout.
XOM offers stable income with a 12.55% ROE and analyst consensus price target of $163.71, suggesting modest upside. Risks include declining revenue trends and oil price volatility, but low breakeven costs in the Permian Basin provide resilience. Institutional sentiment is cautiously optimistic, with 38.89% of analysts rating it a buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
